News
Dividend policy remains a key theme. SPG declared a total dividend of $2.25 per share, with an ex‑dividend date of 2026‑09‑09 and a payment date of 2026‑09‑30. The dividend yield stands at 4.13%, with a forward yield of 4.18%. Although the payout ratio exceeds 1.0, indicating dividends are currently financed from cash reserves or debt, the company...
11/09/2026 | Simon Property Group, Inc.
On capital‑markets activity, SPG’s majority‑owned operating partnership completed the sale of $800 million in senior notes on September 16 2026. The offering comprised $400 million of 5.250% Notes due 2032 and $400 million of 5.650% Notes due 2036, with a weighted‑average term of 7.7 years and a weighted‑average coupon rate of 5.450%. Net proceeds...
11/09/2026 | Simon Property Group, Inc.
Simon Property Group (SPG) reported robust second‑quarter 2026 results, with Real Estate Funds From Operations (FFO) of $3.29 per share, surpassing the Zacks Consensus Estimate of $3.18 by 3.46% and up 7.9% year over year. Total revenues reached $1.79 billion, beating the consensus of $1.71 billion by 4.49% and rising 19.5% from the prior year‑ago...
11/09/2026 | Simon Property Group, Inc.
Financially, NRIX’s shares have risen 38.5 % year‑to‑date, outperforming the industry’s 7.4 % growth, and the company has been upgraded to a Zacks Rank #2 (Buy). The upgrade reflects an upward trend in earnings estimates, with analysts steadily raising their forecasts. NRIX is projected to earn –$2.69 per share for the fiscal year ending November 2...
11/09/2026 | Nurix Therapeutics, Inc.
A key milestone for NRIX is its collaboration with Roche (RHHBY), which values up to $2.3 billion and covers 60 % of development costs. This partnership provides NRIX access to Roche’s global resources and commercial capabilities while preserving meaningful economic participation for the company. The deal is viewed as a significant positive for NRI...
11/09/2026 | Nurix Therapeutics, Inc.
Nurix Therapeutics (NRIX) continues to advance its lead candidate bexobrutideg, an oral, brain‑penetrant Bruton's tyrosine kinase (BTK) degrader designed to treat B‑cell malignancies. The first patient was enrolled in the phase III DAYBreak CLL‑306 study, and the company plans to evaluate the drug in combination with venetoclax for chronic lymphocy...
11/09/2026 | Nurix Therapeutics, Inc.
Billings grew 30.2 % year‑over‑year over the last four quarters; five‑year annualized revenue growth remains 35 %, slowing to 24.8 % over the past two years. Market capitalization stands at $3.43 billion. The company’s forward guidance focuses on significant pipeline growth and margin improvement, while the EPS outlook signals near‑term profitabili...
11/09/2026 | Braze, Inc.
Record second‑quarter free cash flow of $22 million and a liquidity pool of $414 million in cash, cash equivalents, restricted cash and marketable securities underscored strong liquidity. Braze also completed a $50 million accelerated share‑repurchase program in August, signaling confidence in its valuation. Non‑GAAP operating income represented 9....
11/09/2026 | Braze, Inc.
Strategically, Braze broadened its AI footprint. The BrazeAI Operator tool and other AI‑enabled features were showcased at the upcoming Braze Forge 2026 conference (Sept. 28‑30, Las Vegas). A three‑year Strategic Collaboration Agreement with AWS was announced to extend market reach and accelerate AI product adoption, including co‑sell and Marketpla...
11/09/2026 | Braze, Inc.
Braze raised its fiscal‑year guidance to revenue of $910–913 million, a 23 % increase at the midpoint, and EPS of $0.64–0.65. Q3 revenue guidance of $229–230 million exceeded consensus estimates of $227.8 million, but EPS guidance of $0.13–0.14 fell short of the $0.16 consensus, prompting a 10 % after‑hours drop. Shares fell 12–20 % following the Q...
11/09/2026 | Braze, Inc.